CytomX Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
CTMX$2.19+2.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands)
| June 30, · December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| (unaudited) | (1) | |||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $49,041 | $38,052 | ||
| Short-term investments | 109,046 | 62,571 | ||
| Accounts receivable | 1,869 | 3,103 | ||
| Prepaid expenses and other current assets | 4,665 | 3,579 | ||
| Total current assets | 164,621 | 107,305 | ||
| Property and equipment, net | 1,946 | 2,467 | ||
| Intangible assets, net | 510 | 583 | ||
| Goodwill | 949 | 949 | ||
| Restricted cash | 1,028 | 1,027 | ||
| Operating lease right-of-use asset | 5,947 | 8,136 | ||
| Other assets | 56 | 66 | ||
| Total assets | $175,057 | $120,533 | ||
| Liabilities and Stockholders' Equity (Deficit) | ||||
| Current liabilities: | ||||
| Accounts payable | $227 | $1,088 | ||
| Accrued liabilities | 11,503 | 12,338 | ||
| Operating lease liabilities - short term | 5,443 | 5,145 | ||
| Deferred revenue, current portion | 22,050 | 67,201 | ||
| Total current liabilities | 39,223 | 85,772 | ||
| Deferred revenue, net of current portion | 10,241 | 26,862 | ||
| Operating lease liabilities - long term | 1,442 | 4,240 | ||
| Other long term liabilities | 4,241 | 4,115 | ||
| Total liabilities | 55,147 | 120,989 | ||
| Commitments and contingencies | ||||
| Stockholders' equity (deficit): | ||||
| Convertible preferred stock | — | — | ||
| Common stock | 2 | 1 | ||
| Additional paid-in capital | 788,083 | 691,095 | ||
| Accumulated other comprehensive (loss) income | 33 | 27 | ||
| Accumulated deficit | (668,208) | (691,579) | ||
| Total stockholders' equity (deficit) | 119,910 | (456) | ||
| Total liabilities and stockholders' equity (deficit) | $175,057 | $120,533 | ||
(1)
The condensed balance sheet as of December 31, 2024 was derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.